Sign in Subscribe

article

A collection of 624 issues

Tumor mutational burden studied as prognostic marker in metastatic CRC receiving immunotherapy

Skip to content The CRC Digest ◇ RESEARCH Tumor mutational burden studied as prognostic marker in metastatic CRC receiving immunotherapy A retrospective cohort study of 221 metastatic CRC patients receiving anti-PD-1/PD-L1 immunotherapy plus chemotherapy assessed tumor mutational burden as a biomarker for survival and quality of life outcomes. (Medicine) This

Newer colonoscope models and texture enhancement imaging improve adenoma detection

Skip to content The CRC Digest ▪ SCREENING Newer colonoscope models and texture enhancement imaging improve adenoma detection Analysis of 28,459 colonoscopies aimed to identify clinical and technological factors most strongly associated with increased adenoma detection rate, including newer colonoscope models and texture and color enhancement imaging. (Scand J Gastroenterol)

Study assesses impact of concurrent palliative care on metastatic CRC patients on systemic therapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Study assesses impact of concurrent palliative care on metastatic CRC patients on systemic therapy A retrospective study of 201 metastatic CRC patients assessed the impact of concurrent multidisciplinary palliative care alongside systemic therapy on patient-reported outcomes and healthcare utilization. (Front Oncol)

Gut microbiome may influence resistance to immunotherapy in MSI-H/dMMR colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Gut microbiome may influence resistance to immunotherapy in MSI-H/dMMR colorectal cancer A narrative review summarizes evidence that the gut microbiome-immune axis regulates antitumor immunity and may mediate both primary and acquired resistance to immune checkpoint inhibitors in MSI-H/dMMR CRC. (Front Cell

Pulmonary artery enlargement observed during bevacizumab therapy in KRAS-mutant colon cancer

Skip to content The CRC Digest Pulmonary artery enlargement observed during bevacizumab therapy in KRAS-mutant colon cancer A retrospective study of 150 patients with KRAS-mutant colon cancer investigated whether serial thoracic CT demonstrates progressive enlargement of the main pulmonary artery during bevacizumab-based chemotherapy. (Cancer Chemother Pharmacol) This content is informational

Fear of recurrence and coping strategies in CRC survivors

Skip to content The CRC Digest Fear of recurrence and coping strategies in CRC survivors A pilot mixed-methods study quantified fear of cancer recurrence using the FCRI Short Form and examined associations with Brief COPE coping domains in 23 patients who underwent CRC surgery. (HCA Healthc J Med) This content

Quality of life and physical function after metastasis treatment in older patients

Skip to content The CRC Digest Quality of life and physical function after metastasis treatment in older patients A Dutch cohort study evaluated long-term quality of life and physical functioning in patients aged ≥70 years with metastatic colorectal cancer treated with curative local surgical or ablative therapy. (Eur J Surg

Rural and Appalachian communities face geographic barriers to colonoscopy access

Skip to content The CRC Digest ▪ SCREENING Rural and Appalachian communities face geographic barriers to colonoscopy access A national geospatial analysis of all contiguous US census tracts quantified colonoscopy provider access and screening prevalence, comparing rural-urban and Appalachian-non-Appalachian regions where CRC incidence and mortality are disproportionately high. (Prev Chronic Dis)

Chemoradiotherapy plus immunotherapy may expand checkpoint blockade benefit in mismatch repair-proficient rectal cancer

Skip to content The CRC Digest ◇ RESEARCH Chemoradiotherapy plus immunotherapy may expand checkpoint blockade benefit in mismatch repair-proficient rectal cancer Adding immune checkpoint blockade to chemoradiotherapy has been associated with pathological complete response rates of 30% or more in pMMR rectal cancer trials, higher than expected with chemoradiotherapy alone, though

Fatigue remains common five years after rectal cancer treatment

Skip to content The CRC Digest ♥ LIVING WITH CRC Fatigue remains common five years after rectal cancer treatment The QoLiRECT study investigated fatigue prevalence at 5 years after rectal cancer surgery using the Piper Fatigue Scale, examining baseline characteristics and treatment-related factors as potential predictors of moderate-severe fatigue. (Acta Oncol)